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Background: Due to the limited data available in literature, the aim of this multi-centre study was to prospectively
compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO)
regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up
of 18 months.
Methods: Among the first 1135 TM patients in the MIOT (Myocardial Iron Overload in Thalassemia) network, we
evaluated those who had received either combined regimen (DFO + DFP, N=51) or DFP (N=39) and DFO (N=74)
monotherapies between the two CMR scans. Iron overload was measured by T2* multiecho technique. Biventricular
function parameters were quantitatively evaluated by cine images.
Results: The percentage of patients that maintained a normal global heart T2* value was comparable between
DFP+DFO versus both monotherapy groups. Among the patients with myocardial iron overload at baseline, the
changes in the global heart T2* and in biventricular function were not significantly different in DFP+DFO compared with
the DFP group. The improvement in the global heart T2* was significantly higher in the DFP+DFO than the DFO group,
without a difference in biventricular function. Among the patients with hepatic iron at baseline, the decrease in liver iron
concentration values was significantly higher with combination therapy than with either monotherapy group.
Conclusions: In TM patients at the dosages used in the real world, the combined DFP+DFO regimen was more
effective in removing cardiac iron than DFO, and was superior in clearing hepatic iron than either DFO or DFP
monotherapy. Combined therapy did not show an additional effect on heart function over DFP.
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To date one of the most imperative need in the field of
thalassemia major (TM) is to treat patients with tai-
lored chelation therapy. Thus, there is the need of com-
paring the efficacy of each chelator using standardized
and validated techniques as a means of assessing
changes in cardiac iron and function and in liver side-
rosis. In the current clinical practice removal of iron
overload can be achieved using subcutaneous deferoxa-
mine (DFO), oral deferiprone (DFP), oral deferasirox
(DFX), as well as combination therapy with deferiprone
and deferoxamine (DFP+DFO). A large body of evi-
dence is present in literature about the comparison be-
tween DFP and DFO in monotherapy [1-3]. However,
few studies have compared each chelator with their
combinations in terms of differential effect in removing
myocardial or liver iron and in improving cardiac func-
tion using T2* magnetic resonance imaging (MRI) or
other validated procedures. In 2007 a randomized pla-
cebo controlled study from Sardinia demonstrated that
combination therapy DFP+DFO was significantly more
effective than DFO in clearing myocardial iron and in
improving left ventricular (LV) ejection fraction (EF) in
mild to moderate iron loaded patients [4]. In the same
population a prospective study showed that combined
chelation therapy DFP+DFO effectively reduced myocar-
dial iron and improved cardiac function in patients with
severe myocardial siderosis and impaired LV function [5].
Another small sized one-year study using changes in liver
iron concentration (LIC) assessed by biopsies showed the
superiority of the combined DFP+DFO therapy with re-
spect to the DFP alone [6]. More recently, a retrospective
observational study from Greece seemed to confirm that
combination therapy was the most rapid chelation regimen
able to improve hepatic and cardiac T2* values [7]. No long
term data are available in literature about observational
prospective comparisons of the effects on cardiac iron and
function and liver iron in TM patients treated with com-
bined DFP+DFO versus DFP in monotherapy.
Cardiovascular magnetic resonance (CMR) is ideally
suited to compare different chelation treatments, pro-
viding highly reproducible and non-invasive measure-
ments of myocardial [8-10] and liver iron burden
[11,12] by the T2* technique. Moreover, CMR is the
gold standard in cardiology for quantifying biventricular
function parameters [13].
As randomized clinical trials are expensive to perform,
networks of thalassemia and CMR centers, that have
agreed to standardize and share their clinical and instru-
mental data, are powerful and recommended to evaluate
chelation regimens in the real life.
The aim of this multi-centre study was to assess pro-
spectively in a large clinical setting of TM patients the
efficacy of combined DFP+DFO versus DFP and versusDFO in monotherapy by quantitative CMR over a follow
up of 18 months.
Methods
Study population
The MIOT (Myocardial Iron Overload in Thalassemia)
project is an Italian network built in 2006 and consti-
tuted at the time of this study by 68 thalassemia centres
and 8 CMR centres where CMR exams are performed
using homogeneous, standardized and validated proce-
dures [14]. All centres are linked by a web-based net-
work, configured to collect and share patients0 data [15].
Among the first 1135 TM patients enrolled in the MIOT
project, 392 performed a CMR follow up study at 18 ± 3
months, according to the protocol. One hundred and four
patients in any treatment regimen were excluded because
they changed the chelation during the follow up time due
to clinical reasons. Moreover, none of these patients
repeated the CMR exam before the modification of the
therapy due to logistic reasons. One hundred and twenty
four patients were not considered because they received
between the two CMR scans different chelation regimens
from those considered in the present study. So, we evalu-
ated prospectively the 164 TM patients who had been
maintained combined DFP+DFO therapy or DFP and
DFO in monotherapy between the two CMR scans
(according to the protocol any change in the chelation
regimen was made within one month after the CMR scan).
Thus, we identified 3 groups of patients: 51 treated with
combined DFP+DFO, 39 treated with DFP and 74 treated
with DFO. Figure 1 shows the patient flow.
Among the 51 patients treated with DFP+DFO, 49
were in DFP+DFO before the first CMR scan and two
switched to DFP+DFO after the first CMR (1 patient from
DFP, 1 patient from DFX). Among the 39 patients treated
with DFP, 35 were in DFP before the first CMR scan and 4
switched to DFP after the first CMR scan (2 patients from
combined DFP+DFO, 1 patient from sequential DFP-DFO
and 1 patient from deferasirox). Among the 74 patients
treated with DFO, 71 were in DFO before the first
CMR scan and 3 switched to DFO after the first CMR
scan (1 patient from DFP, 1 patient from DFX and 1 pa-
tient from sequential DFP/DFX). All chelation regimens
were prescribed based on the current clinical practice
according to clinical/laboratory and instrumental data.
All patients had been regularly transfused since early
childhood and started chelation therapy from the mid-
to-late 1970s on, while patients born after the 1970s
have received chelation therapy since early childhood.
CMR was performed within 1 week before the regularly
scheduled blood transfusion.
The study complied with the Declaration of Helsinki.
All patients gave written informed consent to the proto-
col. The institutional review board approved this study.
Figure 1 The patient flow.
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At all eight centres, CMR was performed using a 1.5
T scanner (GE Signa/Excite HD, Milwaukee, WI, USA).
An eight-element cardiac phased-array receiver surface
coil with breath-holding in end-expiration and ECG-
gating was used for signal reception.
The T2* technique was used for iron overload assess-
ment. Its reproducibility and its transferability within the
MIOT network had been previously demonstrated for
the heart and for the liver [14]. For the heart, a multi-
slice multiecho T2* approach was used. Three parallel
short-axis views (basal, medium and apical) of the LV
were obtained. Each single short-axis view was acquired
at nine echo times (TEs). Acquisition sequence details
are provided in [3,9,16]. For the liver a single transverse
slice was obtained at nine TEs using a T2* gradient–
echo multiecho sequence in a standard way [11]. T2*
images analysis was performed using a custom-written,
previously validated software program (HIPPO MIOTW,
IFC-CNR) [16]. The software plot the myocardial T2*
distribution into a 16-segment LV model according
to the American Heart Association (AHA)/American
College of Cardiology (ACC) standardized myocardial
segmentation [17]. For the heart an exponential + trun-
cation curve fitting model was applied [16]. The global
heart T2* value was obtained by averaging all segmental
T2* values and the T2* value in the mid-ventricular
septum was obtained by averaging T2* values in the mid
anterior septum and the mid inferior septum. The T2*
values measured depend on the MRI scanner and on the
sequence used and different cut off values have been
showed in literature, but it has never been reported
a normal cut off value < 20 ms, that it has been
conventionally assumed as ″conservative″ normal value
[8,14,16,18]. Cardiac iron concentration (CIC) was
derived from T2* values using the formula described by
Carpenter et al. [10]. For the liver, the T2* value was cal-
culated in a large region of interest (ROI) of standard di-
mension, chosen in a homogeneous area of parenchyma
without blood vessels [15]. Care was taken to avoid theROI placement in the posterior lateral (VII) and medial
(VIII) segments, more prone to susceptibility artifacts
[12]. For the liver an exponential + offset curve fitting
model was applied [11]. A liver T2* < 9.2 ms was consid-
ered indicative of a significant load. Using the calibration
curve introduced by Wood et al. [19], this cut-off corre-
sponds to a LIC higher than 3 mg/g dry weight [20].
For the quantification of biventricular function
parameters, steady-state free procession cine images
were acquired during 8-second breath holds in se-
quential 8-mm short-axis slices (gap 0 mm) from the
atrio-ventricular ring to the apex. Images were ana-
lysed in a standard way [13] using MASSW software
(Medis, Leiden, The Netherlands). The inter-center
variability for the quantification of cardiac function
had been previously reported [21]. A LV EF ≥ 57%
[22] and a right ventricular (RV) EF ≥ 55% [23] were
considered normal.
Statistical analysis
All data were analyzed using SPSS version 13.0 statistical
package. Continuous variables were described as mean ±
standard deviation (SD). Categorical variables were
expressed as frequencies and percentages.
For the intra-treatment and the inter-treatment (between
two groups) comparisons the changes between final and
basal values were used for each quantitative variable.
The intra-treatment comparison was performed by
univariate analysis of variance (ANOVA) with repeated
measures.
The inter-treatment comparison for the baseline data
and the changes between final and basal values was per-
formed by the ANOVA. When the Levine test showed het-
eroscedasticy a log transformation or a Welch ANOVA
was applied. If the log-transformation did not normalize
the variable a non parametric Mann–Whitney test was
used. The analysis of covariance (ANCOVA) was used to
correct for variables (basal value, age, serum ferritin and
MRI LIC) significantly different between the two treatment
groups at the baseline and significantly associated to the
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baseline variables.
A P-value <0.05 was considered statistically significant.
Results
Characterization of the whole study population
The mean administered dosages of the chelators were:
1) DFP in combined regimen 61.9 ± 24.3 mg/kg body
weight per day with a frequency of 6.1 ± 1.4 days/
week and DFO in combined regimen 40.7 ± 6.0 mg/kg
body weight per day with a frequency of 3.5 ± 1.1
days/week; 2) DFP in monotherapy 72.6 ± 12.5 mg/kg
body weight with a frequency of 6.8 ± 0.9 days/week;
3) DFO in monotherapy 40.8 ± 6.5 mg/kg body weight
via subcutaneous route on 5.5 ± 0.9 days/week. The
percentage of patients with excellent/good levels of
compliance to the active chelation treatment was not
different between combined DFP+DFO group and DFP
group (90.2% vs 94.9%; P=0.412) or between combined
DFP+DFO group and DFO group (90.2% vs 95.9%;
P=0.197). The mean time between the two CMR scans
was comparable among groups (DFP+DFO 18.0 ± 1.5
months; DFP 17.7 ± 1.5 months; DFO 18.2 ± 1.3
months; P=0.264). The clinically and instrumentally
relevant baseline findings in the three treatment
groups are summarized in Table 1. The combined
group was significantly younger and showed a signifi-
cantly lower chelation starting age than the DFO
group. The percentage of males was significantly lower
in the combined group than in the DFP group. Mean
serum ferritin levels were significantly higher in the
combined group compared to both DFP and DFOTable 1 Descriptive statistics of the treatment groups at base
P Deferiprone group (n = 39)
Age (yrs) 0.136 31.5 ± 5.3
Male (%) 0.022 69.2%
Chel. starting age (yrs) 0.499 5.1 ± 5.1
Pre-transfusion Hb (g/dl) 0.379 9.5 ± 0.7
Ferritin (ng/l) 0.001 941 ± 1541
Global Heart (ms) 0.0001 31.3 ± 11.3
MRI CIC (mg/g dry w) 0.001 0.94 ± 0.79
N seg. with T2* < 20 ms 0.001 3.9 ± 6.2
Mid septum T2* (ms) 0.0001 34.0 ± 13.0
LV EF (%) 0.643 61.8 ± 9.0
LV EDVI (ml/m2) 0.069 91.9 ± 20.0
RV EF (%) 0.336 59.9 ± 8.8
RV EDVI (ml/m2) 0.126 89.7 ± 19.9
Liver T2* (ms) 0.110 8.9 ± 8.0
MRI LIC (mg/g dry weight) 0.330 8.2 ± 8.9
All values are quoted as mean ± SD. The P-values concern the comparison between
groups.groups. The global heart T2* as well as the mid-
ventricular septum T2* values were significantly lower
in the combined group compared to the DFP group
and the DFO group. The number of segments with T2*
value < 20 ms was significantly higher in the combined
group than in DFP and DFO groups. The MRI LIC was
significantly different in combined and DFO groups.
At baseline 108 patients had a global heart T2*
value ≥ 20 ms and they were distributed in the treat-
ment groups as follows: 25 in the combined group,
30 in the DFP group and 53 in the DFO group. At
the follow-up the percentage of patients that main-
tained a normal global heart T2* value was compar-
able for combined and DFP groups (96.0% vs 100%,
P=0.455) as well as for combined and DFO groups
(96.0% vs 98.1%, P=0.541).
At baseline 133 patients had a normal LV EF. Of them,
43 were in the combined group (24 with a global heart
T2* ≥ 20 ms), 31 in the DFP group (25 with a global
heart T2* ≥ 20 ms) and 59 in the DFO group (44 with a
global heart T2* ≥ 20 ms). The percentage of patients
that maintained a normal LV EF was significantly lower
in the combined group than in the DFP group (83.7% vs
100%, P=0.018) while it was not significantly different
between combined and DFO groups (83.7% vs 83.1%,
P=0.929). Among the patients with no significant myocar-
dial iron burden at baseline (global heart T2* ≥ 20 ms) the
percentage of patients that maintained a normal LV EF
was significantly lower in the combined group than in the
DFP group (79.2% vs 100%, P=0.022) while it was not sig-
nificantly different between combined and DFO groups
(79.2% vs 79.5%, P=1.0). Among the patients with a globalline
Combined group (n = 51) Deferoxamine group (n = 74) P
29.6 ± 6.5 32.7 ± 8.5 0.032
45.1% 48.6% 0.719
4.3 ± 4.1 6.6 ± 4.9 0.030
9.6 ± 0.5 9.7 ± 0.6 0.213
1814 ± 1033 1093 ± 1256 0.001
21.5 ± 12.9 28.5 ± 10.7 0.002
2.15 ± 2.38 1.03 ± 0.79 0.001
8.7± 7.0 4.4 ± 5.9 0.001
22.3 ± 14.3 30.6 ± 12.8 0.001
62.6 ± 7.0 61.6 ± 6.0 0.364
84.7 ± 17.6 89.6 ± 20.2 0.164
61.6 ± 6.8 60.9 ± 7.0 0.587
83.8 ± 16.4 88.1 ± 20.5 0.210
6.3 ± 6.8 11.0 ± 7.5 0.0001
10.3 ± 10.1 5.3 ± 6.2 0.003
combined and deferiprone groups and between combined and deferoxamine
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tained a normal LV EF was not significantly different be-
tween combined and DFP groups (89.5% vs 100%, P=1.0)
or between combined and DFO groups (89.5% vs 93.3%,
P=1.0).
At baseline 130 patients had a normal RV EF. Of
them, 44 were in the combined group (21 with a glo-
bal heart T2* ≥ 20 ms), 30 in the DFP group (26
with a global heart T2* ≥ 20 ms) and 56 in the DFO
group (40 with a global heart T2* ≥ 20 ms). The per-
centage of patients who maintained a normal RV EF
was not significantly different between combined
and DFP groups (86.4% vs 96.7%, P=0.230) or be-
tween combined and DFO groups (86.4% vs 87.5%,
P=0.867). Among the patients with a global heart
T2* ≥ 20 ms, the percentage of patients who main-
tained a normal RV EF was not significantly different
between combined and DFP groups (81.0% vs 96.2%,
P=0.158) or between combined and DFO groups
(81.0% vs 92.5%, P=0.220). Among the patients with
a global heart T2* < 20 ms, the percentage of
patients who maintained a normal RV EF was not
significantly different between combined and DFP
groups (91.3% vs 100%, P=1.0) or between combined
and DFO groups (91.3% vs 75.0%, P=0.205).Baseline characteristics in patients with basal global heart
T2* < 20 ms
At baseline 56 patients showed a global heart T2*< 20
ms: 26 in the combined group, 9 in the DFP group and
21 in the DFO group.Table 2 Baseline descriptive statistics of the treatment groups
P Deferiprone group (n = 9)
Age (yrs) 0.358 29.7 ± 5.2
Male (%) 0.700 66.7%
Chel. starting age (yrs) 0.918 5.0 ± 3.5
Mean pre-transfusion Hb (g/dl) 0.180 9.9 ± 0.4
Mean serum ferritin (ng/l) 0.001 1475 ± 2753
Global Heart (ms) 0.112 12.8 ± 3.6
MRI CIC (mg/g dry weight) 0.096 2.20 ± 0.77
N seg. With T2* < 20 ms 0.502 14.8 ± 1.8
Mid septum T2* (ms) 0.194 13.3 ± 5.2
LV EF (%) 0.466 58.9 ± 5.9
LV EDVI (ml/m2) 0.749 90.2 ± 18.5
RV EF (%) 0.023 54.9 ± 5.7
RV EDVI (ml/m2) 0.737 89.3 ± 20.7
Liver T2* (ms) 0.011 7.5 ± 5.0
MRI LIC (mg/g dry weight) 0.018 8.4 ± 12.9
All values are quoted as mean ± SD. The P-values concern the comparison between
groups.The mean administered dosages of the chelators were:
1) DFP in combined regimen 65.2 ± 22.5 mg/kg body
weight per day with a frequency of 6.5 ± 1.1 days/week
and DFO in combined regimen 41.7 ± 6.5 mg/kg body
weight per day with a frequency of 3.3 ± 1.1 days/week;
2) DFP in monotherapy 79.2 ± 7.8 mg/kg body weight
with a frequency of 6.6 ± 1.3 days/week; 3) DFO in
monotherapy 42.2 ± 6.7 mg/kg body weight via subcuta-
neous route on 5.8 ± 0.7 days/week. The percentage of
patients with excellent/good levels of compliance to the
active chelation treatment was not different between
combined and DFP groups (92.3% vs 88.9%, P=0.752) or
between combined and DFO groups (92.3% vs 90.5%,
P=0.823). The characteristics of these treatment sub-
groups at baseline are indicated in Table 2. The com-
bined group was significantly younger than the DFO
group. The serum ferritin levels were significantly higher
in the combined group than in both DFP and DFO
groups. The global heart as well as the mid-ventricular
septum T2* values were significantly lower in the com-
bined versus the DFO group, but not versus the DFP
group. The combined group showed a LV EF compar-
able with both DFP and DFO groups and a RV EF com-
parable to the DFO group but significantly higher than
the DFP group. The MRI LICs were significantly differ-
ent in the combined than in both DFP and DFO groups.Intra-treatment comparisons in patients with basal global
heart T2* < 20 ms
The mean changes between final and basal values of
each variable of interest are shown in Table 3.composed of patients with global heart T2* value < 20 ms
Combined group (n = 26) Deferoxamine group (n = 21) P
27.6 ± 5.7 32.8 ± 6.5 0.005
53.8% 23.8% 0.072
5.3 ± 5.3 6.7 ± 6.0 0.504
9.6 ± 0.5 9.8 ± 0.6 0.217
2135 ± 966 1367 ± 988 <0.0001
10.2 ± 4.3 14.4 ± 4.3 0.002
3.56 ± 2.65 1.99 ± 0.90 0.002
15.2 ± 1.7 13.0 ± 3.3 0.010
10.6 ± 5.4 14.6 ± 5.0 0.012
61.1 ± 8.3 59.9 ± 6.8 0.583
87.5 ± 22.2 89.9 ± 20.5 0.712
60.2 ± 5.7 60.4 ± 6.0 0.927
86.7 ± 19.7 86.1 ± 21.3 0.926
3.5 ± 3.5 8.2 ± 6.4 0.005
14.8 ± 11.8 6.8 ± 7.0 0.003
combined and deferiprone groups and between combined and deferoxamine
Table 3 Inter-treatment (combined vs deferiprone and combined vs deferoxamine) prospective comparisons in
patients with basal global heart T2* < 20 ms
P Deferiprone group (n = 9) Combined group (n = 26) Deferoxamine group (n=21) P
Mean Diff Serum Ferritin (ng/ml) 0.005 −112 ± 241 −679 ± 835 −133 ± 575 0.017
Mean Diff Global Heart T2* (ms) 0.107 +8.8 ± 8.6 +4.5 ± 6.1 +3.7 ± 5.5 0.644
Mean Diff MRI CIC (mg/g dry w) 0.540 −0.36 ± 1.78 −0.75 ± 1.67 −0.35 ± 0.55 0.255
Mean Diff N seg. With T2* < 20 ms 0.100 −6.0 ± 5.6 −2.4 ± 3.8 −2.9 ± 3.7 0.638
Mean Diff Mid-Septum T2* (ms) 0.295 +6.1 ± 7.4 +3.3 ± 7.1 2.9 ± 5.6 0.841
Mean Diff LV EF (%) 0.181 +5.0 ± 6.4 +1.5 ± 6.7 +2.0 ± 6.5 0.802
Mean DIFF LV EDVI (ml/m2) 0.796 −6.0 ± 12.3 −4.6 ± 13.9 −7.7 ± 11.6 0.432
Mean Diff RV EF (%) 0.137 +6.8 ± 3.7 +3.2 ± 6.7 +0.2 ± 8.8 0.187
Mean Diff RV EDVI (ml/m2) 0.909 −6.9 ± 11.7 −7.5 ± 12.5 −5.8 ± 17.1 0.702
Mean Diff Liver T2* (ms) 0.010 +2.0 ± 7.5 +5.7 ± 6.9 +2.9 ± 4.2 0.026
Mean Diff MRI LIC (mg/g/dw) 0.009 −0.1 ± 3.2 −4.9 ± 6.1 −1.7 ± 2.8 0.024
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only in the combined group (P<0.0001).
In all three groups there was a significant improvement
in the global heart T2* values (combined: P=0.001; DFP:
P=0.015 and DFO: P=0.007) and a significant reduction in
the number of segments with an abnormal T2* value
(combined: P=0.004; DFP: P=0.012 and DFO: P=0.002).
Only in the DFP group there was a significant improve-
ment in the LV EF (P=0.045) while the improvement in the
RV EF was significant in both combined (P=0.024) and
DFP (P=0.001) groups. No significant improvement in both
left and right global systolic function was found in the
DFO group. The reduction of the LV end-diastolic volume
index (EDVI) was significant only in the DFO group
(P=0.007) while the reduction of the RV EDVI was signifi-
cant only in the combined group (P=0.006) (Figure 2).
The decrease of MRI LIC values was significant in the
combined group (P=0.001) and in the DFO group
(P=0.002).
Inter-treatment comparisons in patients with basal global
heart T2* < 20 ms
Table 3 shows the P-values referring to the inter-
treatment comparisons.
The reduction in mean serum ferritin levels was sig-
nificant greater in the combined group compared to
both DFP and DFO groups, even adjusting for influential
covariates (P=0.008 and P=0.003, respectively).
The changes in the global heart T2*, in the CIC, in the
mid-ventricular septum T2* and in the number of seg-
ments with a T2* < 20 ms were not significantly different
between the groups. After the correction for influential
covariates the changes in global heart T2* values and
CIC between combined and DFO groups became statis-
tically different (P=0.014 and P=0.002, respectively).
No significant differences in both left and right global
systolic function were found between the groups, alsoadjusting for influential covariates. Also repeating the
ANCOVA for the LVEF including the basal global heart
T2* values, the difference remained not significant (com-
bined group vs DFP group: P=0.324; combined group vs
DFO group: P=0.735). The changes in MRI LIC values
were significantly higher in combined versus DFP and
DFO groups. The significant difference between com-
bined and DFO groups disappeared adjusting for influ-
ential covariates (P=0.102).
Baseline characteristics in patients with basal MRI
LIC > 3 mg/g/dw
At baseline 97 patients showed a MRI LIC > 3 mg/g/dw:
41 in the combined group, 23 in the DFP group and 33
in the DFO group.
The mean administered dosages of the chelators were:
1) DFP in combined regimen 62.9 ± 24.5 mg/kg body
weight per day with a frequency of 6.1 ± 1.4 days/week
and DFO in combined regimen 41.0 ± 6.2 mg/kg body
weight per day with a frequency of 3.4 ± 1.1 days/week;
2) DFP in montherapy 75.8 ± 7.2 mg/kg body weight with
a frequency of 6.6 ± 1.1 days/week; 3) DFO in monother-
apy 41.7 ± 6.6 mg/kg body weight via subcutaneous route
on 5.6 ± 1.1 days/week. The percentage of patients with ex-
cellent/good levels of compliance to the active chelation
treatment was not different between combined and DFP
groups (87.8% vs 91.3%, P=0.667) or between combined
and DFO groups (87.8% vs 93.9%, P=0.370).
The characteristics of these treatment subgroups at
baseline are reported in Table 4. The mean serum fer-
ritin levels were significantly higher in the combined
group than in both DFP and DFO groups.
Intra- and inter-treatment comparisons in patients with
basal MRI LIC > 3 mg/g/dw
The changes in mean serum ferritin values between
the follow up and the baseline were −614 ± 851 ng/l
Figure 2 Intra-treatment comparison between final and basal values for heart iron and function in patients with basal global heart
T2* value < 20 ms.
Pepe et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:1 Page 7 of 11
http://jcmr-online.com/content/15/1/1in combined group, -8.7 ± 518 ng/l in DFP group
and −214 ± 1074 ng/l in DFO group; with a statis-
tical significance only for the combined group
(P<0.0001). The MRI LIC decreased significantly in the
combined group (−3.6 ± 5.8 mg/g/dw; P< 0.0001) and
in the DFO group (−1.0 ± 3.7 mg/g/dw; P= 0.011). In
the DFP group there was not a significant reduction in
the MRI LIC (−2.3 ± 6.9 mg/g/dw; P= 0.071). In
comparison to both DFP and DFO groups, thecombined group showed a significant greater reduction
in mean serum ferritin levels (P=0.019 and P=0.002, re-
spectively), even adjusting for influential covariates
(P=0.018 and P=0.007, respectively). The decrease in
MRI LIC values was higher in the combined versus the
DFP group, with a P-value near to the statistically sig-
nificance (P=0.065); after adjustment for the basal
mean serum ferritin levels the significance was reached
(P=0.048). The decrease in MRI LIC values was
Table 4 Baseline descriptive statistics of the treatment subgroups with liver T2* value < 9.2 ms
P Deferiprone group (n = 23) Combined group (n = 41) Deferoxamine group (n =33) P
Age (yrs) 0.376 30.6 ± 6.1 28.9 ± 6.2 30.3 ± 8.3 0.439
Male (%) 0.108 69.6% 48.8% 51.5% 0.815
Chel. starting age (yrs) 0.548 5.1 ± 5.7 4.2 ± 4.3 5.4 ± 3.9 0.326
Ferritin (ng/l) <0.0001 1347 ± 1782 2101 ± 944 1729 ± 1672 0.009
Liver T2* (ms) 0.733 3.3 ± 2.1 3.6 ± 2.3 4.0 ± 2.0 0.272
MRI LIC (mg/g dry weight) 0.940 12.5 ± 9.5 12.3 ± 10.2 9.6 ± 7.2 0.197
All values are quoted as mean ± SD.
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(P=0.008), even after adjustment for basal mean serum
ferritin levels (P=0.008) (Figure 3).
Discussion
Despite mounting scientific evidence coming from con-
trolled trials on organ specific property of each chelator,
currently in the clinical practice it is yet difficult to es-
tablish which is the most appropriate treatment for TM
patients with and without significant iron overload. A
mounting body of evidence highlights that combined
DFO+DFP therapy is the most effective regimen against
myocardial iron overload [4,5,7,24]. However, in TM
patients no observational study prospectively evaluated
in the real life the efficacy of the combined DFP+DFO
therapy compared to both chelators in monotherapy. With
the large numbers of patients included in its data base, the
MIOT network is ideally situated to provide clear out-
comes with respect to these questions. Moreover, in this
project the myocardial iron burden is quantified by aFigure 3 Inter-treatment and inter-treatment comparisons between f
LIC > 3 mg/g/dw.segmental approach, that can be advantageous due to the
heterogeneous myocardial iron distribution [25,26].
Out of the 164 patients considered in the current study,
the 95% maintained between the two CMR scans the same
chelation regimen that they had before the first CMR scan.
The baseline characteristics of the whole study population
(Table 1) reflect the current clinical practice. As assessed
by mean serum ferritin levels and almost all CMR iron load
parameters, heavily iron-loaded patients received more fre-
quently combined DFP+DFO therapy. Such circumstance
reflects the current evidence that combined DFP+DFO
regimen seems to be the most effective therapy in remov-
ing iron, particularly appropriate in case of diffuse and/or
severe iron overload. In this regards, in order to better
evaluate prospectively the inter-treatment outcomes we
introduced a covariance analysis and we adjusted for vari-
ables (basal value, age, serum ferritin and MRI LIC) sig-
nificantly different between the groups at the baseline
and significantly associated to the dependent variable. In
fact, different baseline iron overload between groups couldinal and basal values for MRI LIC values in patients with basal MRI
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All three groups showed high and comparable levels of
compliance, confirming the intensive combined chela-
tion regimen well-tolerated.
At 18 months of follow up in TM patients with no sig-
nificant myocardial iron overload at baseline we pro-
vided evidence that all the regimens investigated could
be effective as maintenance therapy regarding to the
myocardial iron burden.
In all three groups with significant myocardial iron
burden at baseline (global heart T2* < 20 ms) we found
prospectively a significant improvement of the heart iron
status both at global and segmental analysis (Figure 2).
Conversely, a significant improvement was found for
both left and right global systolic function in the DFP
group and only for the right global systolic function in
the DFP+DFO group; no significant improvement in sys-
tolic heart function (left and/or right) was reported in
patients treated only with DFO (Figure 2). Although the
changes in cardiac function were not significant between
groups, intra-treatment a significant improvement in the
cardiac function (left and/or right ) was found only in
the groups of patients where deferiprone was adminis-
tered (in combined or in monotherapy). The benefit can-
not be due to a total body iron reduction (serum ferritin
and LIC), as DFP was not more effective than the others
chelation regimens in this action, as also previously
demonstrated [2,27]. The most likely explanation for the
benefit on heart function is that the DFP improves myo-
cardial mitochondrial function [28,29]. The DFP is an
ideal chelating agent to cross cellular and subcellular
membranes and it have an adequate affinity for binding
labile iron as it is a small molecular weight bidentate
with a neutral charge and an optimal partition coeffi-
cient to permeate membranes [30]. Our data about the
significant higher efficacy in the DFP group (in particu-
lar in patients with an heart T2* ≥ 20 ms) in maintaining
a normal heart function further supports the effect of
the DFP on myocardial mitochondrial function inde-
pendently to the iron accumulation/clearance. After the
correction for influential covariates our data confirm in
the clinical arena combined DFP+DFO regimen more ef-
fective than subcutaneous DFO in removing heart iron,
as previously demonstrated by both one randomized
clinical trial [4] and two observational studies [5,7].
Surprisingly, we did not find any additional efficacy
in the combined DFP+DFO regimen versus the DFP in
monotherapy in removing heart iron. No randomized
or observational prospective data are available in the
literature about the head to head comparison between
combined DFP+DFO and DFP therapy. Anyway our
observational prospective long term data seem to be
consistent with one observational retrospective studythat showed no additional effects of the combined
DFP+DFO therapy versus the DFP monotherapy in re-
moving heart iron [7]. In order to find an explanation
for this datum, we compared the combined DFP+DFO
therapy in the MIOT network and in the randomized
controlled Tanner0s study [4] in the same baseline con-
dition (patients with a baseline T2* value in the mid-
ventricular septum ≥ 8 ms and ≤ 20 ms). The rate of
clearance of myocardial iron was slightly lower in the
combined therapy in the MIOT network than in that
one of the Tanners0s study (difference between final
and basal geometric means of the mid-ventricular
septum T2* value: 4.46 ms versus 6.0 ms; ratio of geo-
metric means: 1.35 vs 1.50, P=0.397). We found con-
sistent lower DFO frequencies (days/week) in the
MIOT combined regimen versus the Tanner0s trial (3.4
versus 5.0 days/week). One retrospective single center
study showed that the modulation of the days per
week in DFO combined therapy could influence the
rate of removal of excess of iron load [31]. On the
other hand, the variability in the number of DFO infu-
sion days in combined regimen reflects how the com-
bined DFP+DFO therapy has been used in clinical
practice without a definite schedule and probably accord-
ing to the severity of iron burden in the heart and in the
liver. A similar observation was made in the previous
cited observational analysis of the Greek group [7]. The
lower efficacy of the combined DFP+DFO regimen in re-
moving heart iron within the MIOT network could also
justify the lack of a significant improvement in heart
function in the combined group versus the DFO group
found in our study population; conversely in the Tanner0s
study was found a statistically significant greater im-
provement in the LVEF in the combined group compared
to the DFO group [4].
No consistent differences were found between the MIOT
data and the Tanner0s trial [4] in the global dosage, in the
dosage per day or in the frequency per week for the DFP or
in the global dosage or in the dosage per day for the DFO.
In the same population in another prospective study pub-
lished by Tanner et al. [5] about the combined therapy in
patients with severe myocardial siderosis and impaired LV
function, the dose of deferiprone prescribed was 73.9 ±
4.0 mg/kg/day for 7 days per week (patients0number 15)
and at 12 months, this had been decreased to 65.7 ± 10.7
mg/kg/day, with dose reduction necessary in some case due
to mild adverse events. The data were comparable with the
administered dosages of the DFP in combined regimen in
the MIOT Network (61.9 ± 24.3 mg/kg body weight per
day with a frequency of 6.1 ± 1.4 days/week; patients0num-
ber 51). Nevertheless, it is recommended to prescribe and
to maintain the maximum dosage of the DFP (75 mg/Kg/
die) if tolerated, in order to avoid a significant impact on
the efficacy of the combined therapy in the real life.
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(MRI LICs higher than 3 mg/g dry) we found a signifi-
cant reduction in LICs and serum ferritin levels in all
treatments regimens. However, on this issue the inter-
treatment analysis showed the combined regimen signifi-
cantly more effective. These data on the liver accord
with previous studies [4,6].
Additional prospective assessment of the ongoing
MIOT data base will allow to further characterize the
long-term comparative efficacy of these chelation regi-
mens and to determine whether the observed difference
will be maintained or will encounter an intrinsic limit in
the heart chelating efficiency of each regimen. Moreover,
the open enrollment in the MIOT network could in-
crease the number of patients with significant cardiac
iron burden at baseline, in particular in the DFP group.
In fact, the small number of patients with significant
myocardial iron overload at baseline in the DFP group
represents one of the major limit of this study. At any
rate luckily for our patients, it will be difficult to address
this last issue due to the high and widespread quality of
the TM health management in our country.Conclusions
In TM patients prospectively observed for 18 months, at
the dosages used in the real world, combined DFP+DFO
regimen and DFP in monotherapy were not significantly
different in removing myocardial iron and improving
heart function, while combined DFP+DFO therapy was
more effective in the hepatic iron clearance. Combined
DFP+DFO regimen confirmed its higher efficacy versus
subcutaneous DFO in removing heart and liver iron,
without an additional effect on the heart function. Fur-
ther randomized controlled trials at fixed therapeutic
schedules should be designed to verify these findings.
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